The purpose of this study is to evaluate treatment with the investigational drug LY2835219 in addition to hormonal therapy in women with metastatic breast cancer that is positive for hormone receptors (such as receptors for estrogen and progesterone) and negative for the HER2 protein. LY2835219 is designed to inhibit cancer growth by blocking cyclin-dependent kinases (CDK), enzymes which cancer cells need to grow and divide.
Patients in this study will be treated with LY2835219 plus a standard hormonal therapy (such as letrozole, exemestane, tamoxifen, or anastrozole). Some patients receiving exemestane may also receive the drug everolimus, which helps prevent the tumor from developing resistance to hormonal therapy.
All of the medications in this study are taken orally (by mouth).